verification . please help improve this article by adding citations to reliable sources . unsourced material may be challenged and removed . february 2008 learn how and when to remove this template message neurocrine biosciences type public nasdaq nbix industry biotechnology founded 1992 headquarters san diego california u.s. key people bill rastetter chairman kevin c. gorman ceo president number of employees 95 2015 website www.neurocrine.com neurocrine biosciences is a biopharmaceutical company founded in 1992 and located in san diego california . the company took its name from the original focus on therapies for neurological and endocrine diseases and disorders . medications edit on may 16 2006 when the food and drug administration fda denied approval for the 15 milligram dose of indiplon a medication to treat insomnia . neurocrine had developed the drug and was seeking to market it with partner pfizer . as a result of the denial the stock price fell significantly and the company laid off 300 employees in 2006 . in 2007 neurocrine showed a a fourth quarter loss of 128 million including a 94 million write off with a further layoff of half the remaining workforce . 1 in 2010 the company announced that its drug to treat endometriosis had achieved its main and secondary goals in a study . the drug called elagolix reportedly showed statistically significant reductions in dysmenorrhea or pelvic pain during menstruation as well as painful intercourse . 2 as of 2016 the drug being developed in cooperation with abbvie is in phase iii clinical trials . 3 as of 2016 the company has a drug in development called ingrezza for treatment of tardive dyskinesia . there are currently no approved treatments for this condition . the united states food and drug administration has agreed to review the drug s application under fast track priority status . 4 references edit write off swells neurocrine s 4q loss . associated press . 2008 02 05 . neurocrine biosciences shares soar on drug trial . foxbusiness . 2010 05 25 . moore charles august 25 2016 . endometriosis therapy candidate elagolix meeting phase 3 clinical trial primary targets . endometriosis news . retrieved 14 october 2016 . meiling brittany october 11 2016 . fda accepts neurocrine biosciences new drug application . san diego business journal . retrieved 14 october 2016 . this article about a medical pharmaceutical or biotechnological corporation or company is a stub . you can help wikipedia by expanding it . v t e retrieved from https en.wikipedia.org w index.php title neurocrine biosciences & oldid 744340816 categories companies in the nasdaq biotechnology indexbiotechnology companies of the united statescompanies based in san diegopharmaceutical companies established in 1992medical company stubshidden categories articles needing additional references from february 2008all articles needing additional referencespages using infobox company with unsupported parametersall stub articles navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 14 october 2016 at 16 07 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view